FLX Bio., Inc. Announces the Phase 1 Clinical Study of CCR4 Antagonist FLX475 to Begin in Late 2017 ; Appoints Scott J. Antonia to Its Scientific Advisory Board
The company also announced the appointment of Scott J. Antonia, M.D., Ph.D., Chair of the department of thoracic surgery for Moffitt Cancer Center, to its scientific advisory board (SAB).Dr. Antonia serves as the chair of the thoracic oncology department at the H. Lee Moffitt Cancer Center and Research Institute as well as professor of Oncologic Sciences at the University of South Florida College of Medicine. His expertise lies in treating cancer patients through immunotherapeutic strategies to thwart the immunosuppressive mechanisms used by tumors to evade T cell-mediated rejection.